BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Coya Therapeutics Shows Neuroinflammation Decrease with COYA 301 in Alzheimer's

- Coya reports new data illustrating that administration of COYA 301 (low dose Interleukin-2 (IL-2)) in an open- label study in 8 patients with mild to mod...

June 08, 2023 | News

Merck Announces Proteologix as Winner of its North American Advance Biotech Grant

Proteologix to receive in-kind products and services to develop treatments for autoimmune/inflammatory diseases and oncology indications Experts from Me...

June 07, 2023 | News

Acepodia Secures $100 Million Series D Financing to Advance

Series D led by Digital Mobile Venture with participation from additional existing investors Funds will support expansion and progress of oncology pipelin...

June 07, 2023 | News

Gencurix Announces Clinical Research Results At ASCO 2023

Gencurix (KOSDAQ #229000), a leading provider of cancer molecular diagnostics, announced the release of clinical research results directly compa...

June 06, 2023 | News

Massive Bio and TOI Partner to Revolutionize Cancer Care and Research

Under this visionary collaboration, Massive Bio will support TOI with evaluating the eligibility of patients for TOI's active clinical ...

June 05, 2023 | News

YS Biopharma's PIKA Rabies Vaccine Approved for Phase 3 Clinical Trials by Philippines FDA

The Phase 3 clinical trial, which is planned to commence later in 2023, is a multi-center, multi-country study designed to evaluate the safety and immunoge...

June 02, 2023 | News

Aravax doses first patient in Phase 2 peanut allergy clinical trials

Allergy clinical trial centres across Victoria, South Australia, New South Wales, and Western Australia have invited children and ...

June 02, 2023 | News

Avance Clinical at ASCO & BIO 2023: Rising Complexity and Patient Demand in Early Phase Oncology Trials

According to Avance Clinical's Chief Scientific Officer Gabriel Kremmidiotis who is part of the Avance Clinical team attending ASCO:"Recently, Phas...

June 02, 2023 | News

Innovent Collaborates with Merck KGaA to Study Combination Therapy for KRASG12C-mutated NSCLC in China

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality me...

June 02, 2023 | News

Merck Study: mRNA Technology a ‘Game Changer’ for Asia-Pacific Vaccine Manufacturers

87% of respondents deemed mRNA a key modality for the future More than 60% of vaccine makers surveyed plan revamp or new facilities for mRNA m...

June 01, 2023 | News

Immorna Initiates Phase 1 Study of JCXH-105, a Self-Replicating RNA-Based Shingles Vaccine

"The initiation of our FIH study with JCXH-105 is an important milestone for Immorna and for the development of a potential innovative vaccine for Shingles...

May 31, 2023 | News

Menarini Group's ORSERDU® (Elacestrant) Study Advances in Metastatic Breast Cancer

ORSERDU (elacestrant) was approved by the FDA in January 2023 for advanced or metastatic estrogen receptor (ER)-positive, human epidermal growth factor (...

May 30, 2023 | News

Keio and Osaka Universities Present Non-Clinical Data on Stable/Functional-Induced Regulatory T Cells in Autoimmune Models

Their presentation demonstrated that in a murine pemphigus model, S/F-iTregs significantly decreased clinical scores, circulating anti-Dsg3 IgG titers, and...

May 30, 2023 | News

Amplo Biotech Secures Fast Track Funding for Promising Gene Therapy Targeting Collagen Q Deficiency

Under an exclusive licensing agreement, Amplo Biotechnology has gained access to AAV-ColQ data developed by Professor Kinji Ohno's laboratory at&...

May 30, 2023 | News

Stay Connected